Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132035 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
A Phase 1 study of Age-related Wet Macular Degeneration, sponsored by Caregen Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT06132035: Recruiting Phase 1 study of Age-related Wet Macular Degeneration, sponsored by Caregen Co..
NCT06132035 is a Phase 1 study of Age-related Wet Macular Degeneration that is actively recruiting participants, run by Caregen Co.. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06132035, a Phase 1 study of Age-related Wet Macular Degeneration, is actively recruiting participants, sponsored by Caregen Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CG-P5 peptide
- DRUG Aflibercept Injection [Eylea]
Study Locations (7)
Pennsylvania
- CBCC Global Research Site:002 - Erie
- CBCC Global Research Site:007 - Philadelphia
Connecticut
- CBCC Global Research Site:005 - Manchester
Florida
- CBCC Global Research Site:006 - Deerfield Beach
Georgia
- CBCC Global Research Site:001 - Augusta
Indiana
- CBCC Global Research Site:004 - Carmel
North Dakota
- CBCC Global Research Site:003 - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-12-22 |
| Est. Completion | 2025-08 |
| Phase | Phase 1 |
What NCT06132035 shows while recruiting
NCT06132035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Age-related Wet Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06132035 lists 7 locations in 6 states (Pennsylvania, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT06132035 about?
NCT06132035 is a clinical study titled "Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration". This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
What is the current status of trial NCT06132035?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2023-12-22. Estimated completion is 2025-08.
What conditions does trial NCT06132035 study?
This clinical trial studies the following conditions: Age-related Wet Macular Degeneration.
What interventions are being tested in trial NCT06132035?
The interventions under investigation include: Placebo (DRUG), CG-P5 peptide (DRUG), Aflibercept Injection [Eylea] (DRUG).
Who is sponsoring clinical trial NCT06132035?
This trial is sponsored by Caregen Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132035 being conducted?
This trial has 7 study locations across Connecticut, Florida, Georgia, Indiana, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06132035's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI